Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bactiguard Holding ABCHIX:BACTBS 60 Cash-to-Debt is 0.28 as of Jun. 2026, which is 47% above its 10-year median of 0.19. GuruFocus rates CHIX:BACTBS with a GF Score™ of 60/100 and a GF Value™ of kr242.56. The stock has 2 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Bactiguard Holding AB ranks worse than 79.1% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bactiguard Holding AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.28.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Bactiguard Holding ABcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Bactiguard Holding AB's Cash-to-Debt or its related term are showing as below:
CHIX:BACTBs'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.19 Max: 0.95
Current: 0.28
During the past 13 years, Bactiguard Holding AB's highest Cash to Debt Ratio was 0.95. The lowest was 0.01. And the median was 0.19.
CHIX:BACTBs's Cash-to-Debt is ranked worse than 79.1% of 842
companies
in the Medical Devices & Instruments industry
Industry Median: 1.635
vs CHIX:BACTBs: 0.28
Bactiguard Holding AB (CHIX:BACTBs) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Bactiguard Holding AB Cash-to-Debt Related Terms
Bactiguard Holding AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CHIX:BACTBS vs ABT, SYK, MDT: Cash-to-Debt Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB (CHIX:BACTBS) has a Cash-to-Debt of 0.28 as of Jun. 2026. This is 47% above median its historical median of 0.19. Over the past decade, Bactiguard Holding AB's Cash-to-Debt has ranged from 0.01 to 0.95. According to the industry distribution chart, Bactiguard Holding AB ranks #666 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 79.1%.
Is Bactiguard Holding AB's Cash-to-Debt too high?
Bactiguard Holding AB's current Cash-to-Debt of 0.28 is 47% above median its 10-year median of 0.19. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.95. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Bactiguard Holding AB's value of 0.28 is 82.9% below this industry median. Based on the distribution chart, Bactiguard Holding AB ranks #666 out of 842 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bactiguard Holding AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #666 out of 842 companies for Cash-to-Debt. This places Bactiguard Holding AB in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Bactiguard Holding AB's value of 0.28 is 82.9% below this benchmark. Historically, Bactiguard Holding AB's own Cash-to-Debt has ranged from 0.01 to 0.95 over the past decade. While the company's 10-year median is 0.19 vs. the industry median of 1.64, Bactiguard Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 842 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bactiguard Holding AB's current Cash-to-Debt of 0.28 is 82.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current Cash-to-Debt is 0.28, which is 47% above median its own 10-year median of 0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current Cash-to-Debt of 0.28. The stock's GF Value™ is kr242.56, compared to a current price of kr128.60 — trading 47% below its estimated fair value. The current Cash-to-Debt is 0.28, which is 47% above median its 10-year median of 0.19 and 82.9% below the Medical Devices & Instruments industry median of 1.64. Bactiguard Holding AB's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current Cash-to-Debt is 0.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 47% below its estimated GF Value™ of kr242.56.
Key valuation signals for CHIX:BACTBS:
Cash-to-Debt: 0.28 (47% above median its 10-year median of 0.19)
GF Value™: kr242.56 vs. price of kr128.60 (47% below fair value)
Industry Position: 82.9% below the Medical Devices & Instruments median (#666 of 842)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
60GF Score
Get the complete analysis for CHIX:BACTBS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
